Piper Jaffray analyst David Amsellem raised his price target for Pacira Pharmaceuticals to $93 after the company announced a settlement with the FDA regarding its litigation surrounding the promotion of Exparel and the label. The settlement is "exceedingly favorable" since it confirms that Exparel is broadly indicated for a range of surgeries, Amsellem tells investors in a research note. A "meaningful uptick" in volume growth is likely with the "shackles now off" Pacira's sales team, the analyst contends. He reiterates an Overweight rating on the name.